LATS1 and LATS2 expressions have been reported as significant markers for good prognosis in patients with gastric cancer (Son et al. 2017), reduced LATS1 correlated with poor outcome with breast cancer patients (Takahashi et al. 2005), and reduced LATS2 correlated with poor survival in acute lymphoblastic leukemia (Jiménez-Velasco et al. 2005). Here, LATS2 is linked to breast carcinoma.